AAREY DRUGS & PHARMACEUTICALS
|
AAREY DRUGS & PHARMACEUTICALS Last 5 Year Financial Ratios History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 1.39 | 1.41 | 1.67 | 1.49 | 2.58 |
| CEPS(Rs) | 2.40 | 2.10 | 2.27 | 2.11 | 3.37 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 51.54 | 47.78 | 46.45 | 45.34 | 43.85 |
| Tax Rate(%) | 26.72 | 34.05 | 12.34 | 37.25 | 34.69 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 1.52 | 0.61 | 1.63 | 1.84 | 2.31 |
| EBIT Margin(%) | 2.21 | 2.27 | 2.44 | 2.12 | 2.45 |
| Pre Tax Margin(%) | 1.15 | 1.29 | 1.34 | 1.43 | 2.04 |
| PAT Margin (%) | 0.84 | 0.85 | 1.18 | 0.90 | 1.33 |
| Cash Profit Margin (%) | 1.44 | 1.26 | 1.60 | 1.28 | 1.73 |
| Performance Ratios | |||||
| ROA(%) | 1.35 | 1.36 | 1.58 | 1.41 | 2.74 |
| ROE(%) | 2.81 | 3.02 | 3.82 | 3.33 | 6.31 |
| ROCE(%) | 5.57 | 6.38 | 6.09 | 6.28 | 9.87 |
| Asset Turnover(x) | 1.61 | 1.60 | 1.34 | 1.56 | 2.06 |
| Sales/Fixed Asset(x) | 11.33 | 12.87 | 11.86 | 12.83 | 15.88 |
| Working Capital/Sales(x) | 4.01 | 4.07 | 3.43 | 4.09 | 5.35 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.09 | 0.08 | 0.08 | 0.08 | 0.06 |
| Receivable days | 101.68 | 122.43 | 171.77 | 142.04 | 110.48 |
| Inventory Days | 33.63 | 30.87 | 29.14 | 18.51 | 11.91 |
| Payable days | 75.13 | 93.08 | 124.60 | 108.80 | 86.14 |
| Valuation Parameters | |||||
| PER(x) | 36.49 | 23.84 | 26.76 | 15.93 | 16.03 |
| PCE(x) | 21.23 | 16.07 | 19.64 | 11.24 | 12.30 |
| Price/Book(x) | 0.99 | 0.71 | 0.96 | 0.52 | 0.94 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 0.41 | 0.27 | 0.39 | 0.23 | 0.24 |
| EV/Core EBITDA(x) | 14.57 | 10.17 | 13.59 | 9.29 | 8.47 |
| EV/EBIT(x) | 18.56 | 12.01 | 15.96 | 10.94 | 9.86 |
| EV/CE(x) | 0.96 | 0.75 | 0.95 | 0.63 | 0.93 |
| M Cap / Sales | 0.31 | 0.20 | 0.32 | 0.14 | 0.21 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -0.35 | 19.19 | -5.09 | -14.98 | 41.43 |
| Core EBITDA Growth(%) | 4.39 | 11.34 | 9.24 | -25.68 | 20.55 |
| EBIT Growth(%) | -3.25 | 10.78 | 9.48 | -26.48 | 12.37 |
| PAT Growth(%) | -1.40 | -14.09 | 24.20 | -42.47 | 0.62 |
| EPS Growth(%) | -1.40 | -15.29 | 12.38 | -42.47 | -7.31 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.34 | 0.26 | 0.24 | 0.33 | 0.13 |
| Current Ratio(x) | 1.81 | 1.78 | 1.70 | 1.61 | 1.73 |
| Quick Ratio(x) | 1.53 | 1.48 | 1.49 | 1.44 | 1.62 |
| Interest Cover(x) | 2.08 | 2.31 | 2.22 | 3.10 | 5.93 |
| Total Debt/Mcap(x) | 0.35 | 0.36 | 0.25 | 0.63 | 0.13 |
Compare Financial Ratios of peers of AAREY DRUGS & PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| AAREY DRUGS & PHARMACEUTICALS | ₹360.2 Cr | 8.5% | 11.9% | 37.1% | Stock Analytics | |
| ADANI ENTERPRISES | ₹363,881.0 Cr | 2.2% | -8.1% | 9.2% | Stock Analytics | |
| ADITYA INFOTECH | ₹49,843.6 Cr | -1.7% | 14.6% | 195.5% | Stock Analytics | |
| AEGIS LOGISTICS | ₹47,955.4 Cr | -5.8% | -1.1% | 73.5% | Stock Analytics | |
| PREMIER ENERGIES | ₹41,082.6 Cr | -0.3% | 0.7% | -11% | Stock Analytics | |
| REDINGTON | ₹29,992.8 Cr | -1.9% | -1.2% | 35.1% | Stock Analytics | |
AAREY DRUGS & PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| AAREY DRUGS & PHARMACEUTICALS | 8.5% |
11.9% |
37.1% |
| SENSEX | 3.1% |
1% |
-9.1% |
You may also like the below Video Courses
